Related Experiment Video
Updated: Jun 18, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
Published on: May 6, 2013
Induced Genetic Deletion of Cell Division Autoantigen 1 in Adulthood Attenuates Diabetes-Associated Renal Fibrosis
Pacific Huynh1, Yuxin Yang1, Hua Tian1
1Department of Diabetes, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
Abstract:
Cell Division Autoantigen 1 (CDA1) has been shown to play a role in enhancing transforming growth factor beta (TGFβ) signaling, leading to fibrosis in diabetic kidney disease (DKD) using mouse strains with global CDA1 gene deletion. In these models, diabetes has been induced, leading to DKD in the absence of CDA1. It is still unknown whether inhibition of CDA1 activity after onset of diabetes in the presence of CDA1 can attenuate renal fibrosis in vivo. Thus, we examined the effect of inducing genetic deletion of CDA1 in adulthood in mice using a tamoxifen-activated estrogen receptor fused cyclization recombinase (ERCre)-Locus of cross-over in P1 (LoxP) system. Male mice at 6-8 weeks of age were rendered diabetic with streptozotocin (STZ) or injected with buffer alone to serve as non-diabetic controls. Five weeks later, genetic deletion of CDA1 was induced by tamoxifen administration in CDA1Flox/ERCre mice, with mice injected with vehicle to serve as CDA1 wildtype controls. Kidney tissues were analyzed 5 weeks after deletion of CDA1. Tamoxifen administration reduced CDA1 gene expression by ~80% in CDA1Flox/ERCre mice. Renal levels of phosphorylated Smad3 and expression of profibrotic genes as well as accumulation of extracellular matrix proteins (ECMs) such as collagens III and IV were increased in diabetic mice, and induced deletion of CDA1 led to attenuation of these parameters. Therefore, targeting CDA1 after onset of diabetes in mice where CDA1 was initially expressed is able to attenuate diabetes-associated renal injury, providing the impetus to target this pathway in order to reduce diabetic kidney disease.
Insights
Targeting Cell Division Autoantigen 1 (CDA1) after diabetes onset in mice can reduce kidney fibrosis. Inhibiting CDA1 attenuated key markers of renal injury and extracellular matrix accumulation in diabetic kidney disease models.
Area of Science:
- Nephrology
- Molecular Biology
- Pathology
Background:
- Cell Division Autoantigen 1 (CDA1) enhances transforming growth factor beta (TGFβ) signaling, contributing to fibrosis in diabetic kidney disease (DKD).
- Previous studies used global CDA1 gene deletion models to show its role in DKD.
- The effect of CDA1 inhibition after diabetes onset in the presence of CDA1 remains unclear.
Purpose of the Study:
- To investigate if inhibiting CDA1 activity after diabetes onset can attenuate renal fibrosis in vivo.
- To examine the therapeutic potential of targeting CDA1 in established diabetic kidney disease.
Main Methods:
- Utilized a tamoxifen-inducible Cre-Lox system (ERCre-LoxP) for adult-onset genetic deletion of CDA1 in mice.
- Induced diabetes using streptozotocin (STZ) in male mice (6-8 weeks old).
- Administered tamoxifen to induce CDA1 deletion in diabetic and control mice, analyzing kidney tissues 5 weeks post-deletion.
Main Results:
- Tamoxifen administration reduced CDA1 gene expression by approximately 80% in CDA1Flox/ERCre mice.
- Diabetic mice showed increased renal levels of phosphorylated Smad3 and profibrotic genes.
- Induced CDA1 deletion attenuated the accumulation of extracellular matrix proteins (collagens III and IV) in diabetic kidneys.
Conclusions:
- Targeting CDA1 after the onset of diabetes in mice with pre-existing CDA1 expression can attenuate diabetes-associated renal injury.
- Inhibition of CDA1 shows promise as a therapeutic strategy to reduce kidney fibrosis in diabetic kidney disease.
- These findings provide a rationale for targeting the CDA1 pathway in DKD treatment.
More Related Videos
10:03Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction
Type I Diabetes II: Pathophysiology
Type II Diabetes I: Introduction
Type II Diabetes II: Pathophysiology
Diabetic Nephropathy